Flavia Ejzykowicz

2.5k total citations
42 papers, 367 citations indexed

About

Flavia Ejzykowicz is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Oncology. According to data from OpenAlex, Flavia Ejzykowicz has authored 42 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 21 papers in Economics and Econometrics and 12 papers in Oncology. Recurrent topics in Flavia Ejzykowicz's work include Economic and Financial Impacts of Cancer (19 papers), Renal cell carcinoma treatment (17 papers) and Health Systems, Economic Evaluations, Quality of Life (15 papers). Flavia Ejzykowicz is often cited by papers focused on Economic and Financial Impacts of Cancer (19 papers), Renal cell carcinoma treatment (17 papers) and Health Systems, Economic Evaluations, Quality of Life (15 papers). Flavia Ejzykowicz collaborates with scholars based in United States, United Kingdom and France. Flavia Ejzykowicz's co-authors include Ralph P. Insinga, Josephine Feliciano, Thomas Burke, S Traoré, Kristel Vandormael, David J. Vanness, David Cella, Cristina Ivanescu, Swapnil Rajpathak and Melissa Hamilton and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes Care and The Lancet Oncology.

In The Last Decade

Flavia Ejzykowicz

33 papers receiving 363 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Flavia Ejzykowicz United States	9	173	158	100	84	65	42	367
Danielle Crawley United Kingdom	12	112 0.6×	146 0.9×	70 0.7×	142 1.7×	33 0.5×	33	381
Muriel Licour France	10	158 0.9×	111 0.7×	235 2.4×	59 0.7×	35 0.5×	27	560
N. Varol United Kingdom	7	89 0.5×	76 0.5×	137 1.4×	57 0.7×	15 0.2×	26	294
Raymond Henderson United Kingdom	8	70 0.4×	53 0.3×	33 0.3×	51 0.6×	71 1.1×	14	339
Norman G. Nicolson United States	11	130 0.8×	52 0.3×	121 1.2×	67 0.8×	12 0.2×	24	332
P. Stattin Sweden	7	184 1.1×	257 1.6×	66 0.7×	186 2.2×	16 0.2×	17	512
Teresa Parli United States	9	96 0.6×	279 1.8×	65 0.7×	73 0.9×	12 0.2×	20	393
Cheng‐Ming Peng Taiwan	9	129 0.7×	65 0.4×	40 0.4×	73 0.9×	18 0.3×	40	263
Shiying Kong Canada	10	236 1.4×	132 0.8×	12 0.1×	39 0.5×	30 0.5×	38	364
Heather Beckwith United States	11	180 1.0×	58 0.4×	50 0.5×	95 1.1×	13 0.2×	22	365

Countries citing papers authored by Flavia Ejzykowicz

Since Specialization

Citations

This map shows the geographic impact of Flavia Ejzykowicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flavia Ejzykowicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flavia Ejzykowicz more than expected).

Fields of papers citing papers by Flavia Ejzykowicz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Flavia Ejzykowicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flavia Ejzykowicz. The network helps show where Flavia Ejzykowicz may publish in the future.

Co-authorship network of co-authors of Flavia Ejzykowicz

This figure shows the co-authorship network connecting the top 25 collaborators of Flavia Ejzykowicz. A scholar is included among the top collaborators of Flavia Ejzykowicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Flavia Ejzykowicz. Flavia Ejzykowicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schadendorf, Dirk, et al.. (2024). Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study. European Journal of Cancer. 213. 115099–115099.

Schadendorf, Dirk, Hussein Tawbi, Evan J. Lipson, et al.. (2024). Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC).. Journal of Clinical Oncology. 42(16_suppl). 9557–9557.

Postow, Michael A., Gabriela Burgos, Flavia Ejzykowicz, et al.. (2024). First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.. Journal of Clinical Oncology. 42(16_suppl). 9539–9539. 1 indexed citations

Long, Georgina V., Evan J. Lipson, F. Stephen Hodi, et al.. (2024). First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. Journal of Clinical Oncology. 42(33). 3926–3934. 20 indexed citations

Ornstein, Moshe Chaim, et al.. (2024). Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment. Patient Preference and Adherence. Volume 18. 1729–1739.

Ejzykowicz, Flavia, et al.. (2023). CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL). Value in Health. 26(12). S24–S25.

Cella, David, Toni K. Choueiri, Steven I. Blum, et al.. (2023). Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial.. Journal of Clinical Oncology. 41(16_suppl). 4527–4527.

Escudier, B., Robert J. Motzer, Matthew D. Dyer, et al.. (2022). 1459P Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC). Annals of Oncology. 33. S1212–S1212.

George, Saby, et al.. (2022). POSC321 Estimating Long-Term Survivorship Rates for Previously Untreated Intermediate or Poor (I/P) Risk Advanced Renal Cell Carcinoma (ARCC) Patients Treated with Nivolumab Plus Ipilimumab (NIVO+IPI): Analyses from the CheckMate 214 Trial. Value in Health. 25(1). S210–S210. 1 indexed citations

10.

Cella, David, Robert J. Motzer, Cristina Suárez, et al.. (2022). Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. The Lancet Oncology. 23(2). 292–303. 60 indexed citations

11.

Porta, Camillo, Robert J. Motzer, Flavia Ejzykowicz, et al.. (2021). 668P Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC). Annals of Oncology. 32. S692–S693. 1 indexed citations

12.

Ejzykowicz, Flavia, Xiaohan Chen, Allison Petrilla, et al.. (2020). PCN19 PATIENT CHARACTERISTICS AND FIRST LINE TREATMENTS AMONG MEDICARE PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC). Value in Health. 23. S25–S25. 1 indexed citations

13.

Malcolm, Bill, et al.. (2020). PDG5 Updated Lifetime Survival Estimates for Nivolumab+ipilimumab in Previously Untreated Advanced/Metastatic Intermediate- or Poor-Risk Renal Cell Carcinoma (1L aRCC). Value in Health. 23. S521–S521. 1 indexed citations

14.

Cella, David, Bernard Escudier, Shruti Shally Saggi, et al.. (2020). 714P Time to deterioration in quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214. Annals of Oncology. 31. S562–S562. 3 indexed citations

15.

Malcolm, Bill, et al.. (2020). PCN42 Real-World Effectiveness in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – a Systematic Literature Review Update. Value in Health. 23. S428–S428. 1 indexed citations

16.

Massa, Ilaria, et al.. (2019). PCN80 REAL-WORLD HEALTHCARE COSTS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER IN ITALY. Value in Health. 22. S451–S451. 1 indexed citations

17.

McNeill, Ann, Glenn Davies, Eliza Kruger, et al.. (2019). Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. Diabetes Therapy. 10(2). 473–491. 20 indexed citations

18.

Ejzykowicz, Flavia, et al.. (2019). PCN194 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND. Value in Health. 22. S473–S473. 3 indexed citations

19.

González, Claudio, et al.. (2018). Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study. Endocrinología Diabetes y Nutrición. 65(10). 592–602. 7 indexed citations

20.

Laires, P.A., et al.. (2015). Cost–effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. Journal of Medical Economics. 18(8). 565–572. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact